EirGen Pharma

EirGen Pharma is a specialized CDMO with a strong reputation for high-potency and cytotoxic oral solid dose manufacturing, operating from a purpose-built facility in Waterford, Ireland. The company leverages over 20 years of collective experience to serve over 120 pharmaceutical clients across 60 countries, supported by key regulatory approvals from the FDA, EMA, and others. With a current capacity of 520 million dosage units annually and a planned expansion to 1 billion units by 2027, EirGen is positioned for growth in the complex generics and specialty medicine markets. Its business model is entirely service-based, generating revenue from development, manufacturing, and packaging contracts.

Specialized CDMO capabilities in high-containment Oral Solid Dose (OSD) manufacturing for HPAPI/cytotoxic compounds, end-to-end OSD development (tablets, capsules), advanced softgel formulation, and integrated packaging/serialization.

EirGen competes in the global CDMO market, specifically against other specialists in high-potency and complex oral solid dose manufacturing. Differentiators include its strong regulatory track record (zero FDA 483s), dedicated high-containment facilities, and integrated service offering from development to packaging.